ArticleFrontiers in endocrinology2025
Association of serum chemokine (C-C motif) 21 and receptor (C-C motif) 7 with Hashimoto's thyroiditis--a preliminary clinical investigation.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artemisinin-Related Therapeutic Strategies for Autoimmune Thyroiditis: Chemokine-Receptor Networks, Spatial Thyroid Biology, and Molecular Mechanisms.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the associations of serum chemokine C-C motif 21 (CCL21) and chemokine C-C motif receptor 7 (CCR7) levels with the Hashimoto's thyroiditis. Methods: We recruited 244 subjects (183 with Hashimoto's thyroiditis and 61 healthy controls) from the Second People's Hospital of Huai'an City. Patients with Hashimoto's thyroiditis were divided into three groups according to the type of thyroid autoantibody: a. Double-positive group [elevated both thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb)]; b. TgAb group (elevated TgAb only); c. TPOAb group (elevated TPOAb only), they were further stratified according to thyroid function. We analyzed the between-group differences in the serum CCL21 and CCR7 levels which were quantified by enzyme-linked immunosorbent assay in all subjects. Results: Compared with the healthy control group, the Hashimoto's thyroiditis group had significantly increased serum CCL21 [154.92 (147.01, 165.34) vs 123.74 (118.02,129.22), p<0.001] and CCR7 [19.15 (18.19, 19.71) vs 16.47 (15.88, 17.14), p<0.001], decreased free triiodothyronine, and increased thyroid stimulating hormone, TgAb, and TPOAb. Correlation analysis revealed that serum CCL21 levels were positively correlated with TgAb and TPOAb levels. Univariate binary logistic regression analysis showed that elevated serum CCL21 [OR = 2.944, 95% CI (1.464, 5.919), p=0.002] was significantly associated with Hashimoto's thyroiditis. The results of receiver operating characteristic curve analysis indicated that CCL21 has value for the diagnosis of Hashimoto's thyroiditis [AUC (95% CI)=0.998 (0.996-1.000), p<0.001]. Subgroup analysis suggested that serum CCL21 levels were significantly higher in the double-positive group than in the TgAb and TPOAb groups. Conclusion: Serum CCL21 is significantly elevated in patients with Hashimoto's thyroiditis and correlates with both TgAb and TPOAb levels, suggesting that it is closely related to Hashimoto's thyroiditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.